Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gluten Sensitivity in Non-Celiac Patients (GS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Second University of Naples
Sponsor:
Information provided by (Responsible Party):
Laura de Magistris, Second University of Naples
ClinicalTrials.gov Identifier:
NCT01485341
First received: November 17, 2011
Last updated: September 14, 2014
Last verified: September 2014

November 17, 2011
September 14, 2014
June 2011
December 2014   (final data collection date for primary outcome measure)
Symptoms evaluation according to 3 scales: score after 2 weeks of gluten ingestion [ Time Frame: Change from baseline at 2 weeks ] [ Designated as safety issue: Yes ]
The evaluation will be made according to the score calculated on the basis of three evaluation scales: "Gastrointestinal Symptom Rating Scale "(GSRS), modified, provides a score ranging MIN=15/MAX=60; Extra-gastrointestinal symptoms evaluation scale, proposed on the basis of the symptoms most frequently observed in GS patients, provides a score ranging MIN=9/MAX=34; VQV scale proposed to evaluate the quality of life, provides a score ranging MIN=16/MAX=64. Total score can be no less than 37 (MIN) and not more than 146 (MAX), with a cut-off of 55.
Symptoms evaluation according to 3 scales: total score after 2 weeks of gluten ingestion [ Time Frame: Change from baseline at 2 weeks ] [ Designated as safety issue: Yes ]
The evaluation will be made according to the total score calculated on the basis of three evaluation scales: "Gastrointestinal Symptom Rating Scale "(GSRS), modified, provides a score ranging MIN=15/MAX=60; Extra-gastrointestinal symptoms evaluation scale, proposed on the basis of the symptoms most frequently observed in GS patients, provides a score ranging MIN=9/MAX=34; VQV scale proposed to evaluate the quality of life, provides a score ranging MIN=16/MAX=64. Total score can be no less than 37 (MIN) and not more than 146 (MAX), with a cut-off of 55.
Complete list of historical versions of study NCT01485341 on ClinicalTrials.gov Archive Site
  • Bio-Markers to differentiate GS and CD [ Time Frame: Change from baseline at 2 weeks ] [ Designated as safety issue: Yes ]
    The identification of possible markers (serological, gut barrier function, immunological and expression of tight junctions constitutive proteins) that may be of help to differentiate, in humans, the condition of gluten sensitivity (GS) from that of Celiac Disease (CD); these markers might be of help in the early diagnosis of GS versus CD especially when the serology is discordant.
  • Symptoms evaluation according to 3 scales: scores 2 weeks after completion of intervention [ Time Frame: Return to baseline values at 4 weeks ] [ Designated as safety issue: Yes ]
    The evaluation will be made according to the score calculated on the basis of three evaluation scales: "Gastrointestinal Symptom Rating Scale "(GSRS), modified, provides a score ranging MIN=15/MAX=60; Extra-gastrointestinal symptoms evaluation scale, proposed on the basis of the symptoms most frequently observed in GS patients, provides a score ranging MIN=9/MAX=34; VQV scale proposed to evaluate the quality of life, provides a score ranging MIN=16/MAX=64. Total score can be no less than 37 (MIN) and not more than 146 (MAX), with a cut-off of 55.
  • Bio-Markers to differentiate GS and CD [ Time Frame: Change from baseline at 2 weeks ] [ Designated as safety issue: Yes ]
    The identification of possible markers (serological, gut barrier function, immunological and expression of tight junctions constitutive proteins) that may be of help to differentiate, in humans, the condition of gluten sensitivity (GS) from that of Celiac Disease (CD); these markers might be of help in the early diagnosis of GS versus CD especially when the serology is discordant.
  • Symptoms evaluation according to 3 scales: total score 2 weeks after completion of intervention [ Time Frame: Return to baseline values at 4 weeks ] [ Designated as safety issue: Yes ]
    The evaluation will be made according to the total score calculated on the basis of three evaluation scales: "Gastrointestinal Symptom Rating Scale "(GSRS), modified, provides a score ranging MIN=15/MAX=60; Extra-gastrointestinal symptoms evaluation scale, proposed on the basis of the symptoms most frequently observed in GS patients, provides a score ranging MIN=9/MAX=34; VQV scale proposed to evaluate the quality of life, provides a score ranging MIN=16/MAX=64. Total score can be no less than 37 (MIN) and not more than 146 (MAX), with a cut-off of 55.
Not Provided
Not Provided
 
Gluten Sensitivity in Non-Celiac Patients
Double Blind Randomized Placebo Controlled Multicenter Trial (Gluten vs Placebo) in Gluten Sensitive Subjects

The idea is to evaluate if the so called "Gluten Sensitivity" is a real clinical entity. Gluten sensitive (GS) persons are defined as those patients, being neither celiac or allergic to weat, who develop symptoms following gluten consumption. This will be achieved by evaluating a global symptom score in GS patients receiving gluten compared to those receiving placebo (primary end point). Symptoms to be evaluated: gastrointestinal (Gastrointestinal Symptom Rating Scale, GSRS); not-gastrointestinal (specifically built evaluation scale); VQV scale, built to evaluate quality of life. Gluten or placebo will be administered daily (10 g) for 15 days; for the 15 days before and 15 after all patients will stay on Gluten Free Diet (GFD). Besides clinical evaluation (each week for 6 weeks), intestinal permeability testing and blood sampling will be requested for the identification of possible markers (serological, gut barrier function, immunological and expression of tight junctions constitutive proteins) that may be of help to differentiate the condition of gluten sensitivity (GS) from that of Celiac Disease (CD)(secondary end point). Inclusion and exclusion criteria for patients enrolling are strictly dependant on the given "Gluten sensitivity" definition. We expect to experience a worsening of gastrointestinal and extra-gastrointestinal symptoms, from hours to days, with an increase in the overall symptom score, above the cut off, in at least 45% of GS subjects enrolled and that have received gluten compared to GS who received placebo.

Gluten is the most important protein component of some grains, notably wheat, rye, and barley, which are the basis for a variety of flour and wheat derived alimentary products consumed throughout the world (bread, pasta, pizza etc). However the "engineering" of gluten-containing grains created the conditions for human diseases related to gluten exposure. These forms of gluten intolerance represent a heterogeneous set of conditions, including wheat allergy, Gluten Sensitivity and Celiac Disease, that, combined, affect about 10% of the general population. The frequency of not-celiac gluten intolerance is however still unknown, even though it is possible that these conditions have been undiagnosed and under-diagnosed by the physicians for long time. The state of immune responsiveness to wheat antigens, represents a complex process, and its establishment and maintenance are not completely elucidated. The most frequent diseases caused by wheat ingestion are T cell-mediated disorders, IgE-mediated allergic reactions and celiac disease (CD).

However, besides CD and wheat allergy, there are cases of gluten reactions in which neither allergic nor autoimmune mechanisms are involved. These are generally defined as gluten sensitivity (GS). Some individuals, who experience distress when eating gluten-containing products and show improvement when following a gluten-free diet, may have GS instead of CD. GS patients are unable to tolerate gluten and develop an adverse reaction when eating gluten that usually, and differently from CD, does not lead to small intestinal damage. While the gastrointestinal symptoms in GS may resemble those associated with CD, the overall clinical picture is generally less severe and is not accompanied by the concurrence of tTG autoantibodies or autoimmune disease. Typically the diagnosis is made by exclusion, and an elimination diet and "open challenge" (i.e., the monitored reintroduction of gluten-containing foods) are most often used to evaluate whether health improves with the elimination or reduction of gluten from the diet.

This has two major aims:

  1. Evaluation of the effective dependence from the gluten of the clinical alterations presented by subjects with gluten sensitivity (GS). The study will be done after a period of gluten-free diet (washout of 15 days), comparing two groups of GS subjects: given gluten or placebo (15 days), followed by a further period (15 days) on gluten free diet .
  2. identification of possible markers (serological, gut barrier function, immunological and expression of tight junctions constitutive proteins) that may be of help to differentiate, in humans, the condition of gluten sensitivity (GS) from that of Celiac Disease (CD); these markers might be of help in the early diagnosis of GS versus CD especially in the case of discordant serology.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Gluten Sensitivity
  • Dietary Supplement: gluten
    gluten is administered once a day at 10g/day for 15 days
  • Dietary Supplement: rice starch
    rice starch is administered once a day at 10 g/day for 15 days
  • Active Comparator: gluten
    gluten is administered blindly versus placebo for 15 days at 10 g/day
    Intervention: Dietary Supplement: gluten
  • Placebo Comparator: rice starch
    placebo (rice starch) will be administered blindly versus gluten for 15 days at 10 g/day
    Intervention: Dietary Supplement: rice starch
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
March 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients with age between 18-65 with signs/symptoms compatible with gluten-triggered disorders
  • Patients testing negative for celiac disease either by biopsy Marsh 0-1 or those who are HLA-DQ2 and DQ8 negative, as well as tTG and EMA negative
  • Patients that improved on a gluten free diet

Exclusion Criteria:

  • Subjects diagnosed with celiac disease (positive TTG and/or EMA, and histology positive with Marsh II or above);
  • Subjects diagnosed with wheat allergy
  • Subjects with Type 1 Diabetes (T1D)
  • Subjects with Inflammatory Bowel Disease (ulcerative colitis or Crohn's disease)
  • Pregnancy
  • Subjects with Helicobacter Pylori infection and other gastrointestinal infection
Both
18 Years to 65 Years
No
Contact: Laura de Magistris, PhD +39-81-5665112 laura.demagistris@unina2.it
United States,   Italy
 
NCT01485341
61-2-9-2011
Yes
Laura de Magistris, Second University of Naples
Second University of Naples
Not Provided
Principal Investigator: Anna Sapone, MD, PhD Second University of Naples
Second University of Naples
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP